2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting
ESMO Open. 2024;9(2):102195.
Herrstedt J, Clark-Snow R, Ruhlmann CH, et al., on behalf of the participants of the MASCC–ESMO Consensus Conference 2022
- Nausea and vomiting are considered amongst the most troublesome adverse events for patients receiving antineoplastics.
- The guideline covers emetic risk classification, prevention and management of treatment-induced nausea and vomiting.
- The Consensus Committee consisted of 34 multidisciplinary, health care professionals and three patient advocates.
- Recommendations are based on evidence-based data (level of evidence) and the authors’ collective expert opinion (grade).
- All recommendations are for the first course of antineoplastic therapy; modifications may be needed in subsequent courses.